Tavapadon is a medicine used to treat Parkinson's disease. It's taken as a pill once a day. It works by acting like dopamine, a brain chemical that helps control movement.
Every report comes from a Lived member, sent anonymously.
Have you tried Juvmo (Tavapadon) for Parkinson's Disease?
Tavapadon, sold under the brand name Juvmo, is a prescription tablet for adults with Parkinson's disease. Parkinson's develops when nerve cells in the brain stop making enough dopamine, a chemical messenger that helps control movement, which leads to slowness, stiffness, tremor and problems with balance. Tavapadon is a dopamine agonist: a medicine that acts on the brain's dopamine receptors in place of the missing dopamine. The FDA approved it in 2026. It was tested in two situations. In early Parkinson's, it was used on its own by people who had not yet started levodopa, the most widely used Parkinson's medicine. In more advanced Parkinson's, it was added to levodopa for people whose levodopa wears off between doses. It has not been compared directly with other Parkinson's medicines, and it is not approved for children.
Dopamine passes its signal on by attaching to receptors, which come in two broad families. Older dopamine agonists act mainly on the D2-type receptors. Tavapadon instead acts on the D1 and D5 receptors, and it is a partial agonist, meaning it switches those receptors on but less strongly than dopamine itself would. By standing in for some of the missing dopamine signaling, it helps the brain's movement circuits work more normally. Researchers designed it this way hoping to improve movement while causing fewer of the side effects linked to D2-type stimulation. That idea has not yet been tested in a head-to-head trial, and tavapadon still causes the familiar dopamine-related side effects described below. Like other Parkinson's medicines, it eases symptoms; there is no cure for Parkinson's disease.
Tavapadon is taken by mouth once a day, with or without food. Treatment starts at a very small dose, 0.25 mg, and is increased in small steps every few days using a six-week titration pack, reaching the usual maintenance dose of 5 mg around day 41. If needed, the prescriber can raise it in 5 mg steps, about every two weeks, up to a maximum of 15 mg once a day. The slow start gives the body time to adjust and reduces nausea and dizziness; the prescriber may stretch the steps out further if side effects are a problem. If a dose is missed, take it when you remember on the same day. If the day has passed, skip it and continue the next day as usual; never take two doses to make up for one. Some other medicines change how often tavapadon should be taken, so the schedule may differ from this pattern.
Nausea is the most common side effect, affecting about a quarter of people in the early-Parkinson's trials. Headache, dizziness, tiredness, a changed sense of taste, vomiting, dry mouth and anxiety are also common. In people also taking levodopa, the most frequent effects were nausea, involuntary movements, dizziness, headache, hallucinations and low blood pressure on standing. Side effects tend to be most troublesome while the dose is being increased: most people who stopped because of side effects did so during that phase. Tavapadon can make blood pressure drop when you stand up, causing lightheadedness, nausea, sweating, falls or fainting. This is most likely early in treatment and after a dose increase, so get up slowly from sitting or lying down, and tell the care team if it keeps happening. Some people develop hallucinations (seeing, hearing or feeling things that are not there), confusion or paranoid thinking. This was more common in people 65 and older and in those also taking levodopa. Tavapadon can also cause or worsen dyskinesia, the jerky or writhing involuntary movements that some people with Parkinson's get from their medicines. Both should be reported to the prescriber, who may lower the dose of tavapadon or of another Parkinson's medicine. Like other dopamine medicines, tavapadon can cause intense urges to gamble, spend money, binge eat or have sex that feel hard to control. People often do not recognize these changes in themselves, so it helps for a partner or family member to know to watch for them. Report any such urges to the prescriber; in some people they stopped after the dose was lowered or the medicine stopped.
Tavapadon is broken down by a liver enzyme called CYP3A, so medicines that block or speed up that enzyme can make it much stronger or much weaker. Strong or moderate blockers, such as the antifungal medicines itraconazole and fluconazole, raise tavapadon levels. They should be avoided during the dose build-up, and if one is started later, tavapadon is taken less often (every three or seven days) for as long as the other medicine continues. Strong blockers also raise the risk of hallucinations. Medicines that speed up the enzyme, such as carbamazepine (a seizure medicine), efavirenz (an HIV medicine) and the herbal supplement St. John's wort, can lower tavapadon levels enough to weaken it; strong ones are not recommended with tavapadon, and moderate ones mean it is taken more often. Tavapadon can in turn change the levels of some other medicines. Tell the prescriber and pharmacist about every medicine and supplement, including when one is stopped. People with a major psychotic disorder such as schizophrenia need a careful discussion first, because tavapadon can worsen psychosis, and some medicines used to treat psychosis can worsen Parkinson's symptoms. There is little information on use during pregnancy or breastfeeding, so anyone pregnant, planning pregnancy or nursing should talk this through with the prescriber. It has not been studied in severe liver disease or in kidney failure requiring dialysis.
The first six weeks are spent building up to the maintenance dose, and this is when nausea, dizziness and lightheadedness are most likely. After that, the prescriber judges whether to stay at 5 mg or go higher based on how movement improves and how well the medicine is tolerated. The benefit in the trials was real but measured. In early Parkinson's, people on tavapadon scored about 1.5 to 2.6 points better than those on placebo after six months on a 52-point questionnaire about everyday tasks such as dressing, eating and walking. In people already on levodopa, tavapadon added about an hour a day of good "on" time, when movement works well without troublesome involuntary movements, and cut "off" time, when symptoms return between doses, by about an hour. Responses vary, and the trials lasted about six months, so longer-term experience is still building. Follow-up visits usually check blood pressure, movement, any involuntary movements and mood, and ask about hallucinations or new urges. Dose changes and stopping should be planned with the prescriber.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Juvmo (Tavapadon), what you've noticed, or ask the community a question.